ClinicalTrials.gg
CompletedNCT01256567Updated Jun 18, 2014Results posted

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

A Phase 1 interventional study of Ramucirumab and Docetaxel in Breast Cancer and Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
76th of 80
7 · median 138
Started
2010
the only one that year
Phase 1
17 of 88
3 open now
Registered
41st of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 76th largest by enrollment of the 80 interventional ones that give a count, is the only one that started in 2010, is one of 17 in phase 1, and was the 41st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the safety and tolerability of the anti-VEGFR-2 monoclonal antibody ramucirumab drug product in combination with docetaxel in Japanese participants with metastatic, or locally advanced breast cancer, with the aim of confirming the recommended dose of ramucirumab drug product (DP) in combination with docetaxel.

03

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is Japanese
  • The participant has an (ECOG) performance status of 0 or 1
  • The participant has a histopathologically or confirmed diagnosis of breast adenocarcinoma that is now or locally-recurrent and inoperable with curative intent
  • The participant has measurable and/or non-
  • The participants' primary and/or metastatic tumor is Human Epidermal Growth Factor Receptor 2 () negative
  • The participant received neo or adjuvant taxane therapy ≥ 6 months prior to the study
  • The participant received neo adjuvant or adjuvant biologic therapy ≥ 6 weeks prior to the study
  • The participant completed all prior radiotherapy ≥ 3 weeks prior to the study registration date
  • The participant received prior hormonal therapy for breast cancer in the neo adjuvant, adjuvant,and/or the metastatic setting ≥ 2 weeks prior to the study registration date
  • The participant's (LVEF) is within normal ranges
  • The participant has adequate hematologic, hepatic, and coagulation function.
  • Eligible participants of agree to use adequate methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • The participant has a concurrent active other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for >3 years
  • The participant has a known sensitivity to docetaxel
  • The participant has a known sensitivity to agents of similar biologic composition as ramucirumab
  • The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date
  • The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date
  • The participant has received any experimental agents within 4 weeks prior to the study registration date
  • The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  • The participant has Grade 3-4 bleeding within 3 months prior to the study registration date
  • The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy
  • The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders
  • The participant has
  • The participant has known infection or acquired immunodeficiency syndrome related illness
  • The participant is pregnant or lactating
  • The participant has not fully recovered from effects of prior chemotherapy
  • The participant has undergone major surgery within 28 days prior to the study registration date
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    ramucirumab and docetaxel combination

    Biological: Ramucirumab · Drug: Docetaxel

Interventions

  • BiologicalRamucirumab

    Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.

    Also known as: IMC-1121B, LY3009806

  • Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia \>7days; G ≥3 neutropenia with fever ≥38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G ≥3 thrombocytopenia with bleeding requiring platelets; G≥3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G≥2 hyperbilirubinemia ≥5 days; QTc \>500 milliseconds (ms) or increase ≥100 ms or arrhythmia; G≥4 or uncontrollable hypertension; G≥3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay \>2 weeks due to toxicity.

    Time frame: Baseline up to data cut off (approximately 48.3 weeks)

Secondary outcomes

  1. Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity)

    The number of participants with a positive anti-IMC-1121B titer at any point during the study.

    Time frame: Baseline up to data cut off (approximately 48.3 weeks)

  2. Maximum Concentration (Cmax) of Ramucirumab

    Cmax (Cycle 1) and Cmax at steady state (Cmax,ss, Cycle 4) of ramucirumab are provided.

    Time frame: Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)

  3. Area Under the Curve (AUC) of Ramucirumab

    AUC from time zero to infinity (AUC\[0-inf\], Cycle 1) and at steady state (AUC tau, Cycle 4) of ramucirumab are provided.

    Time frame: Day 1 of Cycles 1 and 4 (cycle=21 days)

  4. Half Life (t 1/2) of Ramucirumab

    Time frame: Day 1 of Cycles 1 and 4 (cycle=21 days)

  5. Clearance (Cl) of Ramucirumab

    Clearance (Cycle 1) and at steady state (Clss, Cycle 4) of ramucirumab are provided.

    Time frame: Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)

  6. Steady State Volume of Distribution (Vss) of Ramucirumab

    Time frame: Day 1 of Cycle 1 and 4 (cycle=21 days)

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab and Docetaxel Combination
Started7
Received at least 1 dose of study drug7
Completed6
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Adverse Events

Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia \>7days; G ≥3 neutropenia with fever ≥38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G ≥3 thrombocytopenia with bleeding requiring platelets; G≥3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G≥2 hyperbilirubinemia ≥5 days; QTc \>500 milliseconds (ms) or increase ≥100 ms or arrhythmia; G≥4 or uncontrollable hypertension; G≥3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay \>2 weeks due to toxicity.

Time frame:
Baseline up to data cut off (approximately 48.3 weeks)
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRamucirumab and Docetaxel Combination
Dose Limiting Toxicity (DLT) during Cycle 12
TEAE related to ramucirumab7
SAE related to ramucirumab4
TEAE of Grade ≥3 related to ramucirumab6
TEAE resulting in ramucirumab discontinuation3
TEAE with ramucirumab dose modification/delay5
SecondarySerum Anti-IMC-1121B Antibody Assessment (Immunogenicity)

The number of participants with a positive anti-IMC-1121B titer at any point during the study.

Time frame:
Baseline up to data cut off (approximately 48.3 weeks)
Reported as:
Number · participants
Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity)
participantsRamucirumab and Docetaxel Combination
Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity)0
SecondaryMaximum Concentration (Cmax) of Ramucirumab

Cmax (Cycle 1) and Cmax at steady state (Cmax,ss, Cycle 4) of ramucirumab are provided.

Time frame:
Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Maximum Concentration (Cmax) of Ramucirumab
micrograms per milliliter (mcg/mL)Ramucirumab and Docetaxel Combination
Cmax at Cycle 1261 ± 22
Cmax,ss at Cycle 4 (n=6)335 ± 22
SecondaryArea Under the Curve (AUC) of Ramucirumab

AUC from time zero to infinity (AUC\[0-inf\], Cycle 1) and at steady state (AUC tau, Cycle 4) of ramucirumab are provided.

Time frame:
Day 1 of Cycles 1 and 4 (cycle=21 days)
Reported as:
Geometric mean · micrograms*day/milliliter (mcg*day/mL)
Area Under the Curve (AUC) of Ramucirumab
micrograms*day/milliliter (mcg*day/mL)Ramucirumab and Docetaxel Combination
AUC(0-inf) at Cycle 11700 ± 25
AUC tau at Cycle 4 (n=6)2320 ± 24
SecondaryHalf Life (t 1/2) of Ramucirumab
Time frame:
Day 1 of Cycles 1 and 4 (cycle=21 days)
Reported as:
Geometric mean · days
Half Life (t 1/2) of Ramucirumab
daysRamucirumab and Docetaxel Combination
t1/2 at Cycle 16.57 ± 49
t1/2 at Cycle 4 (n=6)11.9 ± 26
SecondaryClearance (Cl) of Ramucirumab

Clearance (Cycle 1) and at steady state (Clss, Cycle 4) of ramucirumab are provided.

Time frame:
Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)
Reported as:
Geometric mean · milliliters per hour (mL/hr)
Clearance (Cl) of Ramucirumab
milliliters per hour (mL/hr)Ramucirumab and Docetaxel Combination
Clearance at Cycle 113.6 ± 24
Clearance at steady state (Clss) at Cycle 4 (n=6)10.2 ± 24
SecondarySteady State Volume of Distribution (Vss) of Ramucirumab
Time frame:
Day 1 of Cycle 1 and 4 (cycle=21 days)
Reported as:
Geometric mean · liters (L)
Steady State Volume of Distribution (Vss) of Ramucirumab
liters (L)Ramucirumab and Docetaxel Combination
Vss at Cycle 12.96 ± 32
Vss at Cycle 4 (n=6)3.92 ± 18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab and Docetaxel Combination—7/7 (100%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventRamucirumab and Docetaxel Combination
Febrile neutropeniaBlood and lymphatic system disorders3/7
Pleural effusionRespiratory, thoracic and mediastinal disorders2/7
Cardiac failureCardiac disorders1/7
Neutrophil count decreasedInvestigations1/7
Muscular weaknessMusculoskeletal and connective tissue disorders1/7
EpistaxisRespiratory, thoracic and mediastinal disorders1/7
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/7
Most frequent other events
Showing 10 of 81
Most frequent other events
EventRamucirumab and Docetaxel Combination
Oedema peripheralGeneral disorders7/7
EpistaxisRespiratory, thoracic and mediastinal disorders6/7
AlopeciaSkin and subcutaneous tissue disorders6/7
NasopharyngitisInfections and infestations5/7
Neutrophil count decreasedInvestigations5/7
Nail disorderSkin and subcutaneous tissue disorders5/7
Face oedemaGeneral disorders4/7
MalaiseGeneral disorders4/7
Mucosal inflammationGeneral disorders4/7
DysgeusiaNervous system disorders4/7

Baseline characteristics

Age, Customized
Age, Customized(participants)Ramucirumab and Docetaxel Combination
Between 20 and 65 years6
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab and Docetaxel Combination
Female7
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ramucirumab and Docetaxel Combination
Asian7
American Indian or Alaska Native0
Black or African American0
Native Hawaiian or Other Pacific Islander0
White0
Other0
Region of Enrollment
Region of Enrollment(participants)Ramucirumab and Docetaxel Combination
Japan7
08

Study locations

4 sites
  • ImClone Investigational Site
    Hidaka, 350-1298, Japan
  • ImClone Investigational Site
    Matsuyama, 790-0007, Japan
  • Imclone Investigational Site
    Nagoya, 464-8681, Japan
  • ImClone Investigational Site
    Osaka, 540-0006, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Nov 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2010
First posted
Dec 8, 2010
Start
Dec 2010
Primary completionActual
Nov 2012
CompletionActual
Feb 2013
Results first posted
Jun 18, 2014
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01256567
Responsible party
Sponsor
First posted
Dec 8, 2010
Start date
Dec 2010
Primary completion
Nov 2012
Completion
Feb 2013
Results posted
Jun 18, 2014
Last update
Jun 18, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion